COLLEGE OF MEDICINE AND HEALTH
Medicine, Nursing and Allied Health Professions

Loading content

Ms Claire Bewshea

Exeter IBD and Pharmacogenetics Project Manager

 01392 406850

 RILD Building L3/L06C

 

University of Exeter Medical School, RILD Building, RD&E Hospital Wonford, Barrack Road, Exeter, EX2 5DW, UK

Overview

I am currently  working with Dr Tariq Ahmad, Consultant Gastroenterologist, Royal Devon and Exeter Hospital in delivering multi- centre NIHR  research projects in the field of Inflammatory Bowel Disease (IBD).

I graduated from University of Southampton in 1997 with a BSc (Hons) in  Pharmacology and Physiology. During my  time at Southampton  I also completed a industry placement with Bayer plc, and then went to work and train as a Clinical Research Scientist.   I then relocated to the South West and went on to work for  AstraZeneca until  2006.

From 2008 until 2011 I worked for NHS Devon as a Research and Clinical Trials Manager.

I have been working with Dr Tariq Ahmad since March 2011.

 

 

 

 

Qualifications

BSc (Hons) Pharmacology and Physiology 1997

Clinical Research Scientist 1998

 

Career

Boots 1988-1992

Bayer plc 1995-2002

Astrazeneca 2002-2006

NHS Devon 2008-2011

 

 

 

Links

Research

Research interests

Inflammatory Bowel Disease Genetics of drug side effects anti-TNF response.

Research projects

5ASA - 5- AMINOSALICYLATE INDUCED NEPHROTOXICITY IN IBD PRED4 - Predicting Serious Drug Side Effects in Gastroenterology PANTS- Personalising Anti-TNF Therapy in Crohns Disease.

Research networks

National Institute for Health Research Royal Devon and Exeter Hospital Exeter CRF RD&E Blood Sciences British Society of Gastroenterology Crohn's and Colitis UK International Serious Adverse Event Consortium IBD GENETIC Consortium International IBD Genetics Consortium

Publications

Key publications | Publications by category | Publications by year

Key publications


Walker G, Heap G, Bewshea C, Ahmad T, Irving P, Goodhand J (2016). ANTI-TNF PATIENT TREATMENT PREFERENCES: DATA FROM THE PANTS STUDY.  Author URL.

Publications by category


Journal articles

Carrieri D, Bewshea C, Walker G, Ahmad T, Bowen W, Hall A, Kelly SE (In Press). Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting Report. Journal of Medical Ethics Full text.
Sazonovs A, Kennedy N, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea C, Walker G, Perry MH, McDonald TJ, et al (In Press). HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapy.  Abstract.
Bewshea CM, Ahmad T, Kennedy N, Weedon M, Harrison J, Walker G, Goodhand J, Jones S (2019). Association of Genetic Variants in NUDT15 with Thiopurine-Induced Myelosuppression in Patients with Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 321 (8), 773-785. Full text.
Bewshea CM, Ahmad T, Kennedy N, Goodhand J, McDonald T, Green H (2019). Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterology and Hepatology Full text.
Carrieri D, Jackson L, Bewshea C, Prainsack B, Mansfield J, Ahmad T, Hawkins N, Kelly S (2018). Ethical issues in genomic research: Proposing guiding principles co-produced with stakeholders. Clinical Ethics, 13(4), 194-198. Full text.
Walker GJ, Moore L, Heerasing N, Hendy P, Perry MH, McDonald TJ, Debenham T, Bethune R, Bewshea C, Hyde C, et al (2018). Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Aliment Pharmacol Ther, 47(8), 1103-1116. Abstract.  Author URL.
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Vito A, Beckly J, Buurman D, Chaudhary R, et al (2017). Corrigendum: Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis, 11(12). Author URL.
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Annese V, Beckly J, Buurman D, Chaudhary R, et al (2016). Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis, 10(2), 149-158. Abstract.  Author URL.
Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, et al (2015). Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature Genetics, 47(9), 979-986.
Perry M, Bewshea C, Brown R, So K, Ahmad T, McDonald T (2015). Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. Ann Clin Biochem, 52(Pt 6), 672-674. Abstract.  Author URL.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 46(10), 1131-1134. Abstract.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet, 46(10), 1131-1134. Abstract.  Author URL.

Conferences

Walker G, Lin S, Chanchlani N, Thomas A, Moore L, Hendy P, Heerasing N, Green H, Bewshea C, Goodhand J, et al (2019). Prospective cohort to identify factors associated with a delay in diagnosis in patients with inflammatory bowel disease.  Author URL.
Kennedy NA, Heap GA, Hamilton B, Walker GJ, Bewshea CM, Bouri S, Goodhand J, Ahmad T, Consortium PANTSI (2018). CLINICAL EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF ANTI-TNF THERAPY IN CROHN'S DISEASE: 12 MONTH DATA FROM THE PANTS STUDY.  Author URL.
Kennedy N, Heap G, Walker G, Bewshea C, Bouri S, Goodhand J, Ahmad T, Consortium PANTSI (2018). CLINICAL EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF ANTI-TNF THERAPY IN CROHN'S DISEASE: 12-MONTH DATA FROM PANTS.  Author URL.
Kennedy NA, Heap G, Hamilton B, Walker GJ, Bewshea C, Bouri S, Goodhand J, Ahmad T, Consortium PANTSI (2018). Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn's disease: 12-month data from the PANTS study.  Author URL.
Sazonovs A, Kennedy NA, Bewshea CM, Moutsianas L, Walker GJ, De Lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 CONTRIBUTES TO THE DEVELOPMENT OF ANTIBODIES TO ANTI-TNF THERAPY IN CROHN'S DISEASE.  Author URL.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De lange K, Goodhand JR, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 CONTRIBUTES TO THE DEVELOPMENT OF ANTIBODIES TO ANTI-TNF THERAPY IN CROHN'S DISEASE.  Author URL.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's disease.  Author URL.
Walker GJ, Harrison JW, Voskuil MD, Heap GA, Heerasing N, Hendy PJ, Koskela J, Daly MJ, Sokol H, Weersma RK, et al (2018). NUDT15 VARIANTS CONTRIBUTE TO THIOPURINE-INDUCED MYELOSUPPRESSION IN EUROPEAN POPULATIONS.  Author URL.
Walker G, Harrison J, Voskuil M, Heap G, Heerasing N, Hendy P, Koskela J, Daly M, Sokol H, McGovern D, et al (2018). NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations.  Author URL.
Hamilton B, Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand JR, Kennedy NA (2018). PREVALENCE AND PHENOTYPE OF IBD ACROSS PRIMARY AND SECONDARY CARE: IMPLICATIONS FOR COLORECTAL CANCER SURVEILLANCE.  Author URL.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea CM, Ahmad T, Goodhand J, Kennedy NA (2018). PREVALENCE AND PHENOTYPE OF INFLAMMATORY BOWEL DISEASE ACROSS PRIMARY AND SECONDARY CARE: IMPLICATIONS FOR COLORECTAL CANCER SURVEILLANCE.  Author URL.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand J, Kennedy NA (2018). Prevalence and phenotype of inflammatory bowel disease across primary and secondary care: Implications for colorectal cancer surveillance.  Author URL.
Hendy P, Heerasing N, Walker G, Heap G, Bewshea C, Kennedy N, Goodhand J, Harrower T, Hobart J, Spiers A, et al (2017). CLINICAL FEATURES OF DEMYELINATION DURING ANTI-TNF THERAPY: PRELIMINARY OUTCOMES OF THE PRED4 STUDY.  Author URL.
Walker GJ, Moore L, Heerasing N, Hendy PJ, Bewshea C, Goodhand JR, Kennedy NA, Calvert C, Ahmad T (2017). CLINICAL VALIDITY AND UTILITY OF FAECAL CALPROTECTIN IN PRIMARY CARE.  Author URL.
Walker GJ, Harrison JW, Heap GA, Heerasing N, Hendy PJ, Bewshea C, Goodhand JR, Weedon MN, Kennedy NA, Ahmad T, et al (2017). NUDT15 VARIANTS CONTRIBUTE TO THIOPURINE-INDUCED MYELOSUPPRESSION IN EUROPEAN POPULATIONS.  Author URL.
Walker G, Heap G, Bewshea C, Ahmad T, Irving P, Goodhand J (2016). ANTI-TNF PATIENT TREATMENT PREFERENCES: DATA FROM THE PANTS STUDY.  Author URL.
Heap G, Bewshea C, Singh A, Weedon M, Goldstein J, Ebney N, Mulgrew C, D'Souza R, Oram R, Orchard T, et al (2014). A genome wide association study identifying association of the MHC region with 5-aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease.  Author URL.
Heap GA, Singh A, Bewshea C, Weedon MN, Cole A, Creed T, Greig E, Irving P, Lindsay J, Mawdsley J, et al (2014). THIOPURINE INDUCED PANCREATITIS IN INFLAMMATORY BOWEL DISEASE: CLINICAL FEATURES AND GENETIC DETERMINANTS.  Author URL.
Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA, Bell S, Cole A, et al (2014). Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants.  Author URL.
So K, Bewshea C, Heap GA, Muller AF, Daneshmend TK, Hart AL, Orchard TR, Irving PM, Russell RK, Wilson DC, et al (2013). 5-AMINOSALICYLATE (5-ASA) INDUCED NEPHROTOXICITY IN INFLAMMATORY BOWEL DISEASE.  Author URL.
So K, Bewshea CM, Heap GA, Muller AF, Delaney MP, Daneshmend TK, Hart AL, Orchard TR, Irving PM, D'Souza R, et al (2013). 5-Aminosalicylate (5-ASA) Induced Nephrotoxicity in Inflammatory Bowel Disease.  Author URL.

Publications by year


In Press

Carrieri D, Bewshea C, Walker G, Ahmad T, Bowen W, Hall A, Kelly SE (In Press). Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting Report. Journal of Medical Ethics Full text.
Sazonovs A, Kennedy N, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea C, Walker G, Perry MH, McDonald TJ, et al (In Press). HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapy.  Abstract.

2019

Bewshea CM, Ahmad T, Kennedy N, Weedon M, Harrison J, Walker G, Goodhand J, Jones S (2019). Association of Genetic Variants in NUDT15 with Thiopurine-Induced Myelosuppression in Patients with Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 321 (8), 773-785. Full text.
Bewshea CM, Ahmad T, Kennedy N, Goodhand J, McDonald T, Green H (2019). Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterology and Hepatology Full text.
Walker G, Lin S, Chanchlani N, Thomas A, Moore L, Hendy P, Heerasing N, Green H, Bewshea C, Goodhand J, et al (2019). Prospective cohort to identify factors associated with a delay in diagnosis in patients with inflammatory bowel disease.  Author URL.

2018

Kennedy NA, Heap GA, Hamilton B, Walker GJ, Bewshea CM, Bouri S, Goodhand J, Ahmad T, Consortium PANTSI (2018). CLINICAL EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF ANTI-TNF THERAPY IN CROHN'S DISEASE: 12 MONTH DATA FROM THE PANTS STUDY.  Author URL.
Kennedy N, Heap G, Walker G, Bewshea C, Bouri S, Goodhand J, Ahmad T, Consortium PANTSI (2018). CLINICAL EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF ANTI-TNF THERAPY IN CROHN'S DISEASE: 12-MONTH DATA FROM PANTS.  Author URL.
Kennedy NA, Heap G, Hamilton B, Walker GJ, Bewshea C, Bouri S, Goodhand J, Ahmad T, Consortium PANTSI (2018). Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn's disease: 12-month data from the PANTS study.  Author URL.
Carrieri D, Jackson L, Bewshea C, Prainsack B, Mansfield J, Ahmad T, Hawkins N, Kelly S (2018). Ethical issues in genomic research: Proposing guiding principles co-produced with stakeholders. Clinical Ethics, 13(4), 194-198. Full text.
Walker GJ, Moore L, Heerasing N, Hendy P, Perry MH, McDonald TJ, Debenham T, Bethune R, Bewshea C, Hyde C, et al (2018). Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Aliment Pharmacol Ther, 47(8), 1103-1116. Abstract.  Author URL.
Sazonovs A, Kennedy NA, Bewshea CM, Moutsianas L, Walker GJ, De Lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 CONTRIBUTES TO THE DEVELOPMENT OF ANTIBODIES TO ANTI-TNF THERAPY IN CROHN'S DISEASE.  Author URL.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De lange K, Goodhand JR, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 CONTRIBUTES TO THE DEVELOPMENT OF ANTIBODIES TO ANTI-TNF THERAPY IN CROHN'S DISEASE.  Author URL.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's disease.  Author URL.
Walker GJ, Harrison JW, Voskuil MD, Heap GA, Heerasing N, Hendy PJ, Koskela J, Daly MJ, Sokol H, Weersma RK, et al (2018). NUDT15 VARIANTS CONTRIBUTE TO THIOPURINE-INDUCED MYELOSUPPRESSION IN EUROPEAN POPULATIONS.  Author URL.
Walker G, Harrison J, Voskuil M, Heap G, Heerasing N, Hendy P, Koskela J, Daly M, Sokol H, McGovern D, et al (2018). NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations.  Author URL.
Hamilton B, Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand JR, Kennedy NA (2018). PREVALENCE AND PHENOTYPE OF IBD ACROSS PRIMARY AND SECONDARY CARE: IMPLICATIONS FOR COLORECTAL CANCER SURVEILLANCE.  Author URL.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea CM, Ahmad T, Goodhand J, Kennedy NA (2018). PREVALENCE AND PHENOTYPE OF INFLAMMATORY BOWEL DISEASE ACROSS PRIMARY AND SECONDARY CARE: IMPLICATIONS FOR COLORECTAL CANCER SURVEILLANCE.  Author URL.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand J, Kennedy NA (2018). Prevalence and phenotype of inflammatory bowel disease across primary and secondary care: Implications for colorectal cancer surveillance.  Author URL.

2017

Hendy P, Heerasing N, Walker G, Heap G, Bewshea C, Kennedy N, Goodhand J, Harrower T, Hobart J, Spiers A, et al (2017). CLINICAL FEATURES OF DEMYELINATION DURING ANTI-TNF THERAPY: PRELIMINARY OUTCOMES OF THE PRED4 STUDY.  Author URL.
Walker GJ, Moore L, Heerasing N, Hendy PJ, Bewshea C, Goodhand JR, Kennedy NA, Calvert C, Ahmad T (2017). CLINICAL VALIDITY AND UTILITY OF FAECAL CALPROTECTIN IN PRIMARY CARE.  Author URL.
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Vito A, Beckly J, Buurman D, Chaudhary R, et al (2017). Corrigendum: Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis, 11(12). Author URL.
Walker GJ, Harrison JW, Heap GA, Heerasing N, Hendy PJ, Bewshea C, Goodhand JR, Weedon MN, Kennedy NA, Ahmad T, et al (2017). NUDT15 VARIANTS CONTRIBUTE TO THIOPURINE-INDUCED MYELOSUPPRESSION IN EUROPEAN POPULATIONS.  Author URL.

2016

Walker G, Heap G, Bewshea C, Ahmad T, Irving P, Goodhand J (2016). ANTI-TNF PATIENT TREATMENT PREFERENCES: DATA FROM THE PANTS STUDY.  Author URL.
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Annese V, Beckly J, Buurman D, Chaudhary R, et al (2016). Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis, 10(2), 149-158. Abstract.  Author URL.

2015

Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, et al (2015). Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature Genetics, 47(9), 979-986.
Perry M, Bewshea C, Brown R, So K, Ahmad T, McDonald T (2015). Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. Ann Clin Biochem, 52(Pt 6), 672-674. Abstract.  Author URL.

2014

Heap G, Bewshea C, Singh A, Weedon M, Goldstein J, Ebney N, Mulgrew C, D'Souza R, Oram R, Orchard T, et al (2014). A genome wide association study identifying association of the MHC region with 5-aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease.  Author URL.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 46(10), 1131-1134. Abstract.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet, 46(10), 1131-1134. Abstract.  Author URL.
Heap GA, Singh A, Bewshea C, Weedon MN, Cole A, Creed T, Greig E, Irving P, Lindsay J, Mawdsley J, et al (2014). THIOPURINE INDUCED PANCREATITIS IN INFLAMMATORY BOWEL DISEASE: CLINICAL FEATURES AND GENETIC DETERMINANTS.  Author URL.
Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA, Bell S, Cole A, et al (2014). Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants.  Author URL.

2013

So K, Bewshea C, Heap GA, Muller AF, Daneshmend TK, Hart AL, Orchard TR, Irving PM, Russell RK, Wilson DC, et al (2013). 5-AMINOSALICYLATE (5-ASA) INDUCED NEPHROTOXICITY IN INFLAMMATORY BOWEL DISEASE.  Author URL.
So K, Bewshea CM, Heap GA, Muller AF, Delaney MP, Daneshmend TK, Hart AL, Orchard TR, Irving PM, D'Souza R, et al (2013). 5-Aminosalicylate (5-ASA) Induced Nephrotoxicity in Inflammatory Bowel Disease.  Author URL.

Refresh publications

Teaching

Pharmacology

Inflammatory Bowel Disease.

 

Supervision / Group

Back | Edit Profile